Research Publications

Co-founded by a
Bioengineering Pioneer

Dr. Molly Shoichet is internationally renowned for her innovative biomaterials and therapeutic delivery strategies. Shoichet addresses critical questions in medicine with her multidisciplinary research approach that spans drug discovery to drug delivery.

AmacaThera is strategically positioned to develop a pipeline of products that build on cutting-edge inventions in injectable hydrogels, formulation design, drug delivery, affinity release and cell therapy.

For more information about publications related to AmacaThera’s technology, please visit the Shoichet Lab.

Molly DC v2

AmacaGel Platform

2019
A hyaluronan/methylcellulose-based hydrogel for local cell and biomolecule delivery to the central nervous system
M. T. Ho, C. J. Teal, and Molly S. Shoichet.
Published in Brain Research Bulletin, Mar. 2019
2010
Intrathecal delivery of a polymeric nanocomposite hydrogel after spinal cord injury
M. Douglas Baumann, Catherine E. Kang, Charles H. Tator, and Molly S. Shoichet.
Published in Biomaterials, Oct. 2010

Biologics, Cells

2020
Hydrogel-mediated co-transplantation of retinal pigmented epithelium and photoreceptors restores vision in an animal model of advanced retinal degeneration
Nikolaos Mitrousis, Sabiha Hacibekiroglu, Margaret T. Ho, Yves Sauvé, Andras Nagy, Derek van der Kooy and Molly S. Shoichet.
Published in Biomaterials, Oct. 2020
2019
Initial cell maturity changes following transplantation in a hyaluronanbased hydrogel and impacts therapeutic success in the stroke-injured rodent brain
Samantha L. Payne, Anup Tuladhar, Jaclyn M. Obermeyer, Balazs V. Varga, Carter J. Teal, Cindi M. Morshead, Andras Nagy and Molly S. Shoichet.
Published in Biomaterials, Feb. 2019
2019
Controlled release strategy designed for intravitreal protein delivery to the retina.
Vianney Delplace, Arturo Ortin-Martinez, En Leh S. Tsai, Alan N. Amin, Valerie Wallace, and Molly S. Shoichet.
Published in Journal of Controlled Release, Jan. 2019
2016
Encapsulation-free controlled release: Electrostatic adsorption eliminates the need for protein encapsulation in PLGA nanoparticles
Malgosia M. Pakulska, Irja Elliott Donaghue, Jaclyn M. Obermeyer, Anup Tuladhar, Christopher K. McLaughlin, Tyler N. Shendruk and Molly S. Shoichet.
Published in Science Advances, May 2016
2015
A Hyaluronan-Based Injectable Hydrogel Improves the Survival and Integration of Stem Cell Progeny following Transplantation
Brian G. Ballios, Michael J. Cooke, Laura Donaldson, Brenda L. K. Coles, Cindi M. Morshead, Derek van der Kooy and Molly S. Shoichet.
Published in Stem Cell Reports, Jun. 2015
2013
Bioengineered sequential growth factor delivery stimulates brain tissue regeneration after stroke.
Yuanfei Wang, Michael J. Cooke, Nadia Sachewsky, Cindi M. Morshead, and Molly S. Shoichet.
Published in Journal of Controlled Release, Nov. 2013
2012
Tunable growth factor delivery from injectable hydrogels for tissue engineering.
Katarina Vulic and Molly S. Shoichet.
Published in Journal of the American Chemical Society, Jan. 2011
2012
Hydrogel delivery of erthropoietin to the brain for endogenous stem cell stimulation after stroke injury.
Yuanfei Wang, Michael J. Cooke, Cindi M. Morshead, Molly S. Shoichet.
Published in Biomaterials, Dec. 2011

Small molecules

2015
Circumventing the blood-brain barrier: Local delivery of cyclosporin A stimulates stem cells in stroke-injured rat brain.
Anup Tuladhar, Cindi M. Morshead, and Molly S. Shoichet.
Published in Journal of Controlled Release, Oct. 2015
2013
A hydrogel composite system for sustained epi-cortical delivery of Cyclosporin A to the brain for treatment of stroke.
Matthew J. Caicco, Michael J. Cooke, Yuanfei Wang, Anup Tuladhar, Cindi M. Morshead, and Molly S. Shoichet.
Published in Journal of Controlled Release, Mar. 2013
2009
Accelerated release of a sparingly soluble drug from an injectable hyaluronan-methylcellulose hydrogel.
Yuanfei Wang, Yakov Lapitsky, Catherine E. Kang, and Molly S. Shoichet.
Published in Journal of Controlled Release, Dec. 2009

Amacathera Logo

AmacaThera is a clinical-stage biotechnology company transforming therapeutics to make a difference in patient health. Our unique, injectable hydrogel platform provides localized, sustained drug delivery to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer and other hard‑to‑reach target areas.